

## UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 01,496-A)

IN THE APPLICATION OF:

Damian J. Gallina

Serial No. 10/050,655

Filed: January 16, 2002

Title: Compositions and Methods For  
Treating Retroviral Infections

Examiner:

To Be Assigned

Group Art Unit:

1651

RECEIVED  
APR 01 2002  
TECH CENTER 1600/2900

## TRANSMITTAL LETTER

BOX DD

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In regard to the above identified application:

1. We are transmitting herewith the attached:
  - a. Information Disclosure Statement;
  - b. Form PTO-1449;
  - c. Copy of IDS Citations 10/050,655 (15 references);
  - d. Return Receipt Postcard.
2. With respect to additional fees:

☒ No additional fee is required.
3. Please charge any additional fees or credit overpayment to Deposit Account No.13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box DD, Washington, D.C. 20231 on this 18<sup>th</sup> day of March, 2002.

By:

  
John J. McDonnell  
Reg. No. 26,949

APR 01 2002

TECH CENTER 1600/2900

#4  
198  
6/12/02

PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 01,496-A)

IN THE APPLICATION OF:

Damian J. Gallina

Serial No. 10/050,655

Filed: January 16, 2002

Title: Compositions and Methods For  
Treating Retroviral Infections

Examiner: To Be Assigned

Group Art Unit: 1651

INFORMATION DISCLOSURE STATEMENT

Box DD  
Commissioner for Patents  
Washington, D.C. 20231-9999

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application.

Portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective

dates early enough to be "prior art" within the meaning of 35 U.S.C. sections 102 or 103, nor is this submission to be construed as a representation that a search has been made.

### CITED REFERENCES

#### **U.S. Patent Documents**

NONE

#### **Foreign Patent Documents**

NONE

#### **Other Documents**

1. Francis Szoka, et al., "*Mechanism of Targeting to CD44 Positive Breast Tumors*", University of California, San Francisco - School of Pharmacy, Abstract Page # A-13.
2. Pruimboom, et al., "Capsular Hyaluronic Acid-mediated Adhesion of Pasteurella multocida to Turkey Air Sac Macrophages", *Avian Disease*, 1996, Volume 40, Pages 887-893.
3. H. L. Kain, "Experimentelle Untersuchungen zur proliferativen Vitreoretinopathie (PVR)", *Fortschr Ophthalmol*, 1991, Volume 88, Pages 671-676.
4. Stanescu et al., "Interaction Between macrophages And Articular Surfaces: An In Vitro Transmission And Scanning Electron Microscopy Study", *Connective Tissue Research*, 1990, Volume 24, Pages 207-218.
5. Shannon et al., "Participation of Hyaluronic Acid In The Macrophage Disappearance Reaction", *Immunological Communications*, 1980, Volume 9, Number 4, Pages 357-370.
6. Sun, et al., "Expression Profile of Hyaluronidase mRNA Transcripts in the Kidney and in Renal Cells", *Kidney blood Press Research*, 1998, Volume 21, Pages 413-418.
7. Van der Gaag, et al., "The Influence Of High Molecular Weight Sodium Hyaluronate (Healon®) On The Production Of Migration Inhibitory Factor", *IRL Press Limited*, 1987, Volume 6, Pages 1433-1440.

8. Culty, et al., "The Hyaluronan Receptor (CD44) Participates in the Uptake and Degradation of Hyaluronan", The Journal of Cell Biology, Volume 116, Number 4, February 1992, Pages 1055-1062.
9. Poernadaja, et al., "Phagocytic Uptake and Killing of Virulent And Avirulent Strains of Pasteurella Multocida of Capsular Serotype A By Chicken Macrophages", Veterinary Microbiology, 2000, Volume 72, Pages 163-171.
10. Khaldoyanidi et al., "Hyaluronate-Enhanced Hematopoiesis: Two Different Receptors Trigger the Release of Interleukin-1 $\beta$  and Interleukin-6 From bone Marrow Macrophages", Blood, August 1, 1999, Volume 94, Number 3, Pages 940-949.
11. De Carvalho et al., "Effect of Various Digestive Enzymes On The Interaction of Toxoplasma Gondii With Macrophages", Parasitol Research, 1993, Volume 79, Pages 114-118.
12. Denhardt, et al., "Osteopontin As A Means To cope With Environmental Insults: Regulation Of Inflammation, Tissue Remodeling, And Cell Survival", The Journal of Clinical Investigation, May 2001, Volume 107, Number 9, 1055-1061.
13. Denhardt, et al., "Role of Osteopontin In Cellular Signaling And Toxicant Injury", Annual Review of Pharmacology and Toxicology, 2001, Volume 41, Pages 723-749.
14. Leite-de-Moraes, et al., "Natural Killer T Cells: A Potent Cytokine-Producing Cell Population", European Cytokine Network, September 1997, Volume 8, Issue 3, Pages 229-237.
15. Oswald, et al., "Tumor Necrosis Factor Is Required For The Priming of Peritoneal macrophages By Trehalose Dimycolate", European Cytokine Network, December 1999, Volume 10, Issue 4, Pages 533-540.


Respectfully submitted,

**McDonnell Boehnen Hulbert & Berghoff**

Date:

3/18/02

By:

  
John J. McDonnell  
Registration No. 26,949

Form PTO-1449 (modified)

MAR 25 2002

Atty. Docket No.  
01-496-ASerial N.  
10/050,655List of Patents and Publications of Applicant's  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Damian J. GallinaFiling Date:  
January 16, 2002Group:  
1651U.S. Patent Documents  
NoneForeign Patent Documents  
NoneOther Art  
See Page 1 and Page 2

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Francis Szoka, et al., "Mechanism of Targeting to CD44 Positive Breast Tumors", University of California, San Francisco - School of Pharmacy, Abstract Page # A-13.
	C2	Pruimboom, et al., "Capsular Hyaluronic Acid-mediated Adhesion of Pasteurella multocida to Turkey Air Sac Macrophages", Avian Disease, 1996, Volume 40, Pages 887-893.
	C3	H. L. Kain, "Experimentelle Untersuchungen zur proliferativen Vitreoretinopathie (PVR)", Fortschr Ophthalmol, 1991, Volume 88, Pages 671-676.
	C4	Stanescu et al., "Interaction Between macrophages And Articular Surfaces: An In Vitro Transmission And Scanning Electron Microscopy Study", Connective Tissue Research, 1990, Volume 24, Pages 207-218.
	C5	Shannon et al., "Participation of Hyaluronic Acid In The Macrophage Disappearance Reaction", Immunological Communications, 1980, Volume 9, Number 4, Pages 357-370.
	C6	Sun, et al., "Expression Profile of Hyaluronidase mRNA Transcripts in the Kidney and in Renal Cells", Kidney blood Press Research, 1998, Volume 21, Pages 413-418.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications of Applicant's  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents <i>None</i>	Foreign Patent Documents <i>None</i>	Other Art <i>See Page 1 and Page 2</i>
--------------------------------------	---	---

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Van der Gaag, et al., "The Influence Of High Molecular Weight Sodium Hyaluronate (Healon®) On The Production Of Migration Inhibitory Factor", IRL Press Limited, 1987, Volume 6, Pages 1433-1440.
	C8	Culty, et al., "The Hyaluronan Receptor (CD44) Participates in the Uptake and Degradation of Hyaluronan", The Journal of Cell Biology, Volume 116, Number 4, February 1992, Pages 1055-1062.
	C9	Poernadajaja, et al., "Phagocytic Uptake and Killing of Virulent And Avirulent Strains of Pasteurella Multocida of Capsular Serotype A By Chicken Macrophages", Veterinary Microbiology, 2000, Volume 72, Pages 163-171.
	C10	Khaldoynidi et al., "Hyaluronate-Enhanced Hematopoiesis: Two Different Receptors Trigger the Release of Interleukin-1 $\beta$ and Interleukin-6 From bone Marrow Macrophages", Blood, August 1, 1999, Volume 94, Number 3, Pages 940-949.
	C11	De Carvalho et al., "Effect of Various Digestive Enzymes On The Interaction of Toxoplasma Gondii With Macrophages", Parasitol Research, 1993, Volume 79, Pages 114-118.
	C12	Denhardt, et al., "Osteopontin As A Means To cope With Environmental Insults: Regulation Of Inflammation, Tissue Remodeling, And Cell Survival", The Journal of Clinical Investigation, May 2001, Volume 107, Number 9, 1055-1061.
	C13	Denhardt, et al., "Role of Osteopontin In Cellular Signaling And Toxicant Injury", Annual Review of Pharmacology and Toxicology, 2001, Volume 41, Pages 723-749.
	C14	Leite-de-Moraes, et al., "Natural Killer T Cells: A Potent Cytokine-Producing Cell Population", European Cytokine Network, September 1997, Volume 8, Issue 3, Pages 229-237.
	C15	Oswald, et al., "Tumor Necrosis Factor Is Required For The Priming of Peritoneal Macrophages By Trehalose Dimycolate", European Cytokine Network, December 1999, Volume 10, Issue 4, Pages 533-540.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPPE609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)